Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-23T09:03:57.693Z Has data issue: false hasContentIssue false

A Summary of the Third Global Interferon-γ Release Assay Symposium

Published online by Cambridge University Press:  02 January 2015

Antonino Catanzaro*
Affiliation:
Department of Medicine, University of California, San Diego, California
Charles Daley
Affiliation:
Department of Medicine, National Jewish Health, Denver, Colorado; and Department of Medicine, University of Colorado Denver, Aurora, Colorado
*
University of California, San Diego, 9500 Gilman Stein Clinical Research Building MC0643, La Jolla, CA 92093-0643 ([email protected])

Abstract

Studies over the past several decades have dramatically increased our understanding of the immune response to Mycobacterium tuberculosis infection, and advances in proteomics and genomics have led to a new class of immune-diagnostic tests, termed interferon-γ (IFN-γ) release assays (IGRAs), which appear to obviate many of the problems encountered with the tuberculin skin test (TST). Worldwide, 2 IGRAs are currently commercially available. QuantiFERON-TB Gold In-Tube (Cellestis) is a third-generation product that uses an enzyme-linked immunosorbent assay to measure IFN-γ generated in whole blood stimulated with M. tuberculosis–specific antigens. T-Spot-TB (Oxford Immunotec) employs enzyme-linked immunosorbent spot technology to enumerate the number of purified lymphocytes that respond to M. tuberculosis–specific antigens by producing IFN-γ. These in vitro tests measure the host immune response to M. tuberculosis–specific antigens, which virtually eliminates false-positive cross reactions caused by bacillus Calmette-Guérin vaccination and/or exposure to environmental nontuberculous mycobacteria that plague the interpretation and accuracy of the tuberculin skin test (TST). The high specificity of IGRAs, together with sensitivity commensurate with or better than that of the TST, promises an accurate diagnosis and the ability to focus tuberculosis-control activities on those who are actually infected with M. tuberculosis. The Third Global Symposium was held over a 3-day period and was presented by the University of California, San Diego, Continuing Medical Education department; slides and sound recordings of each presentation are available at http://cme.ucsd.edu/igras/syllabus.html. A moderated discussion is also available at http://cme.ucsd.edu/igrasvideo. This document provides a summary of the key findings of the meeting, specifically focusing on the use of IGRAs in screening healthcare worker populations.

Type
Review Article
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.von Pirquét, C. Frequency of tuberculosis in childhood. JAMA 1909I(9):675678.Google Scholar
2.Palmer, CE, Edwards, LB. Identifying the tuberculosis infected: the dual-test technique. JAMA 1968;205(3):167169.Google Scholar
3.Denkinger, CM, Dheda, K, Pai, M. Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011;17(6):806814.Google Scholar
4.Van Zyl-Smit, R, Zwerling, A, Dheda, K, Pai, M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systemic review. PloS ONE 2009;4(12):e8517.Google Scholar
5.Pai, M, Joshi, R, Dogra, S, et al.Serial testing of health care workers for tuberculosis using interferon-γ assay. Am J Respir Crit Care Med 2006;174(3):349355.Google Scholar
6.Rangaka, MX, Wilkinson, KA, Glynn, JR, et al.Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(1): 4555.Google Scholar
7.Diel, R, Goletti, D, Ferrara, G, et al.Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011;37(1):8899.Google Scholar
8.Friedman, LN, Nash, ER, Bryant, J, et al.High rate of negative results of tuberculin and QuantiFERON tests among individuals with a history of positive skin test results. Infect Control Hosp Epidemiol 2006;27(5):436441.CrossRefGoogle ScholarPubMed